$GLUE
Monte Rosa Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022016844 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.020M $6.295M $6.387M
YoY Change 47.7% 80.58% 186.28%
% of Gross Profit
Research & Development $21.34M $20.94M $17.92M
YoY Change 41.2% 43.03% 93.2%
% of Gross Profit
Depreciation & Amortization $1.100M $800.0K $800.0K
YoY Change 89.0% 100.0% 166.67%
% of Gross Profit
Operating Expenses $28.36M $27.23M $24.30M
YoY Change 42.75% 50.26% 111.25%
Operating Profit -$28.36M -$27.23M -$24.30M
YoY Change 42.75% 50.26% 111.25%
Interest Expense $997.0K $628.0K $149.0K
YoY Change 7569.23% 4385.71% 2383.33%
% of Operating Profit
Other Income/Expense, Net $1.044M $762.0K $370.0K
YoY Change 3267.74% -370.21% -147.93%
Pretax Income -$27.32M -$26.47M -$23.93M
YoY Change 37.71% 43.81% 94.95%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$27.32M -$26.47M -$23.93M
YoY Change 37.71% 43.81% 94.95%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$584.6K -$567.2K -$513.6K
COMMON SHARES
Basic Shares Outstanding 46.71M 46.67M 46.63M
Diluted Shares Outstanding 46.73M 46.67M 46.60M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $272.1M $294.1M $317.2M
YoY Change -25.85% -17.62% 88.3%
Cash & Equivalents $112.4M $103.7M $138.3M
Short-Term Investments $159.8M $190.5M $178.9M
Other Short-Term Assets $5.529M $2.900M $3.203M
YoY Change 58.65% 135.96% -2.08%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $295.2M $297.0M $320.4M
YoY Change -20.32% -17.09% 86.58%
LONG-TERM ASSETS
Property, Plant & Equipment $19.38M $15.21M $13.40M
YoY Change 64.26% 70.4% 73.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $148.0K $384.0K $5.333M
YoY Change -91.44% -77.79% 358.16%
Total Long-Term Assets $62.37M $68.01M $25.64M
YoY Change 360.96% 538.48% 188.21%
TOTAL ASSETS
Total Short-Term Assets $295.2M $297.0M $320.4M
Total Long-Term Assets $62.37M $68.01M $25.64M
Total Assets $357.6M $365.1M $346.0M
YoY Change -6.89% -1.05% 91.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.753M $4.294M $4.511M
YoY Change 176.29% -42.46% -38.42%
Accrued Expenses $12.04M $10.48M $7.979M
YoY Change 30.65% 214.87% 352.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.79M $14.77M $12.49M
YoY Change 71.0% 36.9% 37.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $44.72M $48.23M $7.640M
YoY Change 2134.93% 3176.7% 699.16%
Total Long-Term Liabilities $44.72M $48.23M $7.640M
YoY Change 2134.93% 3176.7% 699.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.79M $14.77M $12.49M
Total Long-Term Liabilities $44.72M $48.23M $7.640M
Total Liabilities $66.51M $63.01M $20.13M
YoY Change 351.11% 413.79% 100.36%
SHAREHOLDERS EQUITY
Retained Earnings -$199.8M -$172.4M -$146.0M
YoY Change 102.64% 118.78%
Common Stock $493.4M $476.9M $474.0M
YoY Change 5.02% 9.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $291.1M $302.1M $325.9M
YoY Change
Total Liabilities & Shareholders Equity $357.6M $365.1M $346.0M
YoY Change -6.89% -1.05% 91.58%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$27.32M -$26.47M -$23.93M
YoY Change 37.71% 43.81% 94.95%
Depreciation, Depletion And Amortization $1.100M $800.0K $800.0K
YoY Change 89.0% 100.0% 166.67%
Cash From Operating Activities -$20.60M -$20.50M -$27.40M
YoY Change 15.77% 50.94% 98.36%
INVESTING ACTIVITIES
Capital Expenditures -$1.400M -$2.553M $1.687M
YoY Change -20.23% -5.48% -23.91%
Acquisitions
YoY Change
Other Investing Activities $30.89M -$11.70M -$178.8M
YoY Change 46002.99%
Cash From Investing Activities $29.49M -$14.25M -$180.5M
YoY Change -1846.98% 427.55% 8042.53%
FINANCING ACTIVITIES
Cash Dividend Paid $0.00
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -217.0K 96.00K 153.0K
YoY Change -100.74% -99.95% -99.89%
NET CHANGE
Cash From Operating Activities -20.60M -20.50M -27.40M
Cash From Investing Activities 29.49M -14.25M -180.5M
Cash From Financing Activities -217.0K 96.00K 153.0K
Net Change In Cash 8.672M -34.65M -207.8M
YoY Change -13.05% -118.32% -263.94%
FREE CASH FLOW
Cash From Operating Activities -$20.60M -$20.50M -$27.40M
Capital Expenditures -$1.400M -$2.553M $1.687M
Free Cash Flow -$19.20M -$17.95M -$29.09M
YoY Change 19.71% 64.95% 81.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
CY2021Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
CY2021Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
CY2022Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12325000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
47102000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5320000
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-03-31
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
glue Noncash Lease Expense
NoncashLeaseExpense
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001826457
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40522
dei Entity Registrant Name
EntityRegistrantName
Monte Rosa Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3766197
dei Entity Address Address Line1
EntityAddressAddressLine1
645 Summer Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
949-2643
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
GLUE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46713908
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103664000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
346071000
CY2022Q2 us-gaap Marketable Securities
MarketableSecurities
190481000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2900000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2595000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
297045000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
348666000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15205000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5717000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5338000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
384000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2022Q2 us-gaap Assets
Assets
365056000
CY2021Q4 us-gaap Assets
Assets
366329000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4294000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6558000
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7817000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10080000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2662000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14773000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16638000
CY2022Q2 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2138000
CY2021Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2176000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46095000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q2 us-gaap Liabilities
Liabilities
63006000
CY2021Q4 us-gaap Liabilities
Liabilities
18814000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46873974
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46684658
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46794295
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46535966
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
476939000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
471566000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2458000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2021000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172436000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122035000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
302050000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
347515000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
365056000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
366329000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20936000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14637000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38851000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23910000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6295000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3486000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12682000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
27231000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
18123000
us-gaap Operating Expenses
OperatingExpenses
51533000
us-gaap Operating Expenses
OperatingExpenses
29627000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27231000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18123000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51533000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29627000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
628000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
777000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
20000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
134000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-296000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
230000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-114000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
125000
CY2022Q2 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
0
CY2021Q2 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
0
glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
0
glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
-960000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
762000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-282000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1132000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1054000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26469000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-18405000
us-gaap Net Income Loss
NetIncomeLoss
-50401000
us-gaap Net Income Loss
NetIncomeLoss
-30681000
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.57
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.57
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.63
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.63
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.08
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.08
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-9.03
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-9.03
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46668369
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46668369
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5070554
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5070554
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46632279
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46632279
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3399174
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3399174
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26469000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-18405000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
125000
us-gaap Net Income Loss
NetIncomeLoss
-50401000
us-gaap Net Income Loss
NetIncomeLoss
-30681000
CY2022Q2 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
33000
CY2021Q2 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
-495000
glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
67000
glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
-359000
CY2022Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
358000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
504000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26794000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18900000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50838000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31040000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-48728000
CY2021Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
136000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
252000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12276000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-60616000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2021Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
231172000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
203875000
CY2021Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-495000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1019000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-18405000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
356678000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
347515000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153000
CY2022Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
34000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2251000
CY2022Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
146000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23932000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
325875000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
96000
CY2022Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
33000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2873000
CY2022Q2 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
358000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26469000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
302050000
us-gaap Profit Loss
ProfitLoss
-50401000
us-gaap Profit Loss
ProfitLoss
-30681000
us-gaap Share Based Compensation
ShareBasedCompensation
5124000
us-gaap Share Based Compensation
ShareBasedCompensation
1271000
us-gaap Depreciation
Depreciation
1642000
us-gaap Depreciation
Depreciation
741000
glue Noncash Lease Expense
NoncashLeaseExpense
1659000
glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
-331000
glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
0
glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
-960000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
688000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-663000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2547000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1195000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2196000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
844000
us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
-28000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-70000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47905000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27397000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4240000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4918000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
125000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
230654000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
40000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-194769000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4918000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
143000000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
231000
glue Proceeds From Initial Public Offering Net Of Underwriting Discount
ProceedsFromInitialPublicOfferingNetOfUnderwritingDiscount
15600000
glue Proceeds From Initial Public Offering Net Of Underwriting Discount
ProceedsFromInitialPublicOfferingNetOfUnderwritingDiscount
15600000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
206739000
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
0
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
1395000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
249000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
128000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
249000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
348241000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-242425000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
315926000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
351409000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42863000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108984000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
358789000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103664000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
357060000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
5320000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
1729000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108984000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
358789000
glue Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
0
glue Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
231172000
glue Settlement Of Preferred Stock Tranche Obligation
SettlementOfPreferredStockTrancheObligation
0
glue Settlement Of Preferred Stock Tranche Obligation
SettlementOfPreferredStockTrancheObligation
20640000
glue Common Stock Issuance Costs In Accounts Payable
CommonStockIssuanceCostsInAccountsPayable
0
glue Common Stock Issuance Costs In Accounts Payable
CommonStockIssuanceCostsInAccountsPayable
1469000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
939000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
123000
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-3.5305
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172400000
us-gaap Net Income Loss
NetIncomeLoss
-50400000
us-gaap Net Income Loss
NetIncomeLoss
-30700000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
294100000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7300000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
7400000
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
283946000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
190984000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
503000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
190481000
glue Number Of Marketable Securities Held
NumberOfMarketableSecuritiesHeld
30
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
127700000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19373000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15028000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4168000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2703000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15205000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12325000
CY2022Q2 us-gaap Depreciation
Depreciation
800000
CY2021Q2 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
1600000
us-gaap Depreciation
Depreciation
700000
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
us-gaap Operating Lease Cost
OperatingLeaseCost
2703000
us-gaap Variable Lease Cost
VariableLeaseCost
617000
us-gaap Lease Cost
LeaseCost
3320000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y9M18D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.097
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
48488000
glue Cash Paid For Amount Included In Measurement Of Lease Liabilities
CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities
712000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1400000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
3160000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
8353000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
8583000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
8820000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
7298000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
44360000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
80574000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Company’s board of directors approved a one-for-3.5305 reverse stock split of its issued and outstanding common stock and stock options and a proportional adjustment to the existing conversion ratios for the Company’s preferred stock effective as of June 17, 2021
CY2021Q2 glue Stockholders Equity Note Reverse Stock Split Conversion Ratio
StockholdersEquityNoteReverseStockSplitConversionRatio
1
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46873974
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46684658
CY2022Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
-0
us-gaap Payments Of Dividends
PaymentsOfDividends
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7382284
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5821842
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5563513
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.92
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
70045000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1845375
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.02
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
79679
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
136241
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.00
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7192968
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21414000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1724556
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7589000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
900000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5124000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1271000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26469000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-18405000
us-gaap Net Income Loss
NetIncomeLoss
-50401000
us-gaap Net Income Loss
NetIncomeLoss
-30681000
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.57
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.57
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.63
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.63
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.08
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.08
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-9.03
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-9.03
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46668369
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46668369
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5070554
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5070554
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46632279
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46632279
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3399174
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3399174
CY2022Q2 us-gaap Defined Benefit Plan Administration Expenses
DefinedBenefitPlanAdministrationExpenses
200000
CY2021Q2 us-gaap Defined Benefit Plan Administration Expenses
DefinedBenefitPlanAdministrationExpenses
100000
us-gaap Defined Benefit Plan Administration Expenses
DefinedBenefitPlanAdministrationExpenses
400000
us-gaap Defined Benefit Plan Administration Expenses
DefinedBenefitPlanAdministrationExpenses
200000
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2022Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2021Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
glue Lease Termination Description
LeaseTerminationDescription
The Company may terminate the lease as of any date between February 1, 2023 and June 1, 2023 upon providing 90 days prior notice of such date.

Files In Submission

Name View Source Status
0000950170-22-016844-index-headers.html Edgar Link pending
0000950170-22-016844-index.html Edgar Link pending
0000950170-22-016844.txt Edgar Link pending
0000950170-22-016844-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
glue-20220630.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
glue-20220630.xsd Edgar Link pending
glue-ex31_1.htm Edgar Link pending
glue-ex31_2.htm Edgar Link pending
glue-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
glue-20220630_def.xml Edgar Link unprocessable
glue-20220630_pre.xml Edgar Link unprocessable
glue-20220630_lab.xml Edgar Link unprocessable
glue-20220630_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
glue-20220630_cal.xml Edgar Link unprocessable